+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay



Piperacillin/tazobactam (Tazocin™) seems to be no longer responsible for false-positive results of the galactomannan assay



Journal of Antimicrobial ChemoTherapy 67(7): 1746-1748



Galactomannan (GM) testing is extremely useful for diagnosing invasive aspergillosis in high-risk patients, but false-positive results have been reported in patients treated with piperacillin/tazobactam. The aims of this study are to test if the recent piperacillin/tazobactam (Tazocin™; Pfizer) preparation still contains GM, and if serum GM positivity in haematopoietic stem cell transplant (HSCT) recipients receiving piperacillin/tazobactam can be attributed to this treatment. Serum samples obtained from 1 October 2009 to 31 October 2010 from HSCT recipients for GM testing were analysed. The difference in the rate of positive results (defined as GM ≥ 0.5) in patients receiving and not receiving piperacillin/tazobactam was evaluated. Piperacillin/tazobactam vials from randomly selected batches were tested. Of 1606 samples drawn in the absence of piperacillin/tazobactam therapy, 25 (1.6%) tested positive for GM versus 10 of 394 samples (2.5%) drawn while on piperacillin/tazobactam (P = 0.18). The median GM result of samples drawn on piperacillin/tazobactam was slightly higher than that of samples drawn in the absence of piperacillin/tazobactam (0.141 versus 0.122; P < 0.001). All 90 piperacillin/tazobactam vials from 30 randomly selected batches tested negative for GM, with a median GM value of 0.057 (range: 0.011-0.320). Although some residual GM might still be present in piperacillin/tazobactam, currently available brand piperacillin/tazobactam preparations seem no longer responsible for false-positive GM results.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055010536

Download citation: RISBibTeXText

PMID: 22499998

DOI: 10.1093/jac/dks111


Related references

False-positive results in the galactomannan Platelia™ Aspergillus assay with generic piperacillin/tazobactam. Revista Iberoamericana de Micologia 2019, 2019

False positive galactomannan results in adult hematological patients treated with piperacillin-tazobactam. Revista Iberoamericana de Micologia 24(2): 106-112, 2007

False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clinical Infectious Diseases 38(6): 913-916, 2004

Lack of evidence that false-positive Aspergillus galactomannan antigen test results are due to treatment with piperacillin-tazobactam. Clinical Infectious Diseases 39(9): 1401-2; Author Reply 1402-3, 2004

Reduction in false-positive Aspergillus serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. Journal of Clinical Microbiology 52(6): 2199-2201, 2015

Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clinical Infectious Diseases 38(6): 917-920, 2004

False positive galactomannan Platelia due to piperacillin-tazobactam. Medecine et Maladies Infectieuses 42(1): 10-14, 2012

Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia. Medical Mycology 55(5): 535-540, 2016

Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin). Journal of the Medical Association of Thailand 94 Suppl 1: S196-S202, 2011

Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam. Medycyna Doswiadczalna i Mikrobiologia 50(1-2): 41-46, 1998

Plasmalyte: No Longer a Culprit in Causing False-Positive Galactomannan Test Results. Journal of Clinical Microbiology 54(3): 795-797, 2016

False positivity of the Aspergillus galactomannan Platelia ELISA because of piperacillin/tazobactam treatment: does it represent a clinical problem?. Journal of Antimicrobial ChemoTherapy 62(5): 1109-1112, 2008

Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study. European Journal of Clinical Microbiology and Infectious Diseases 34(7): 1437-1441, 2016

The interaction between piperacillin-tazobactam and Aspergillus galactomannan antigenemia assay: is the story over?. Infection 41(1): 293-294, 2013

Tazocin, a combined dosage form of piperacillin and tazobactam. Antibiotiki i Khimioterapiya 42(2): 5-16, 1997